Taking medication as directed is critical to improving outcomes.
Study finds less than half of prescriptions for PCSK9 inhibitors are approved by insurance companies.
A recent change in calculating non-fasting cholesterol improves accuracy.
A new class of drugs, PCSK9 inhibitors, presents a further treatment option for certain patients at high risk for heart problems.